{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"151.000","floor":"133.000"},"ipodate":{"start":"2021-02-16 00:00:00","end":"2021-02-19 00:00:00"},"minimumcapital":"15252.17","subscribed":"310.00","marketcap":"408.88億","H_marketcap":"65.42億","pe":"195.55","codesrate":"5.00","link":"https://staticpdf.iqdii.com/stockdata/notice/06127/2021/2021021600010_c.pdf","ipopricing":"151.000","resultdate":"2021-02-25 00:00:00","enddate":"2021-02-19 00:00:00","listeddate":"2021-02-26 00:00:00","issuenumber":"4332.48萬","issuenumberhK":"1559.70萬","issuenumberother":"2772.78萬","grayprice":"145.00","sponsors":"中信里昂證券資本市場有限公司","raisemoney":"628610.00萬","use":"1、16.0%或1,005.8百萬港元將用于進一步擴大我們于蘇州的設施網絡乃為我們的未來增長提供必要的支持；\n2、10.0%或628.6百萬港元將用于增強我們的美國業務以迎合客戶對Biomere所提供服務日益增長的需求；\n3、39.0%或2,451.6百萬港元將用于進一步擴大我們于中國的設施網絡及服務能力；\n4、5.0%或314.3百萬港元將用于拓展及深化我們的綜合合同研究組織服務；\n5、20%或1,257.2百萬港元將用于進一步實施我們拓寬藥物研發價值鏈上的綜合服務范圍并拓展海外布局的策略；\n6、10%或628.6百萬港元將用于營運資金及一般企業用途。","shares":100,"leadagent":"中信里昂證券有限公司,美林亞太有限公司,中國國際金融香港證券有限公司,招商證券(香港)有限公司,海通國際證券有限公司,中銀國際亞洲有限公司,招銀國際融資有限公司,交銀國際證券有限公司,工銀國際證券有限公司","bookrunners":"中信里昂證券有限公司,美林亞太有限公司,中國國際金融香港證券有限公司,招商證券(香港)有限公司,海通國際證券有限公司,中銀國際亞洲有限公司,招銀國際融資有限公司,交銀國際證券有限公司,工銀國際融資有限公司","coordinator":"中信里昂證券有限公司,美林亞太有限公司,中國國際金融香港證券有限公司","firstDayOpen":"148.00","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"是","StabilizingManager":"中信里昂證券有限公司","code":"E06127","name":"昭衍新藥","fullname":"北京昭衍新藥研究中心股份有限公司"},"institutioninfo":{"principaloffice":"中國北京經濟技術開發區榮京東街甲5號","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333","chairman":"馮宇霞","secretary":"高大鵬,吳卓明","telephone":"","substantialshareholders":"馮宇霞(23.66%),周志文(12.77%),顧曉磊(5.94%)","principalactivities":"公司是一家專注于藥物非臨床安全性評價研究的領先合同研究組織，正擴展以提供涵蓋藥物研發服務鏈上藥物發現、臨床前和臨床試驗階段的綜合服務。","website":"www.joinn-lab.com"},"managerinfo":[{"managername":"馮宇霞","post":"董事長兼執行董事","rankno":1},{"managername":"左從林","post":"副董事長兼執行董事","rankno":2},{"managername":"高大鵬","post":"總經理兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"Lake Bleu Prime Healthcare Master Fund Limited","shareholding":"1,951,000.0","percentage":4.5,"ReleaseDate":"2021-08-26 00:00:00","relatedparty":"清池資本(香港)有限公司","subsidiary":["Lake Bleu Prime Healthcare Master Fund Limited"],"InverstorType":"基金"},{"institutionname":"CPE Greater China Enterprises Growth Fund","shareholding":"1,797,000.0","percentage":4.1,"ReleaseDate":"2021-08-26 00:00:00","relatedparty":"源峰基金管理有限公司","subsidiary":["CPE Greater China Enterprises Growth Fund","CPE Fund"],"InverstorType":"基金"},{"institutionname":"OrbiMed Funds","shareholding":"1,797,000.0","percentage":4.1,"ReleaseDate":"2021-08-26 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"中國國有企業結構調整基金股份有限公司","shareholding":"1,797,000.0","percentage":4.1,"ReleaseDate":"2021-08-26 00:00:00","relatedparty":"國務院國資委","subsidiary":["中國誠通控股集團有限公司","中國國有企業結構調整基金股份有限公司","中國機械工業集團有限公司","中國商用飛機有限責任公司","中國西電集團公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":31.8},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":6}